Helix Acquisition II today said it has completed its initial public offering of 18.4 million shares at $10 each, including 2.4 million shares as a result of the underwriter’s exercise in full of its over-allotment option.
Formed by Cormorant Asset Management, Helix II intends to focus on the healthcare industry.
No warrants were included in the offering.
Cormorant has “indicated the interest” of buying 2.5 million shares as well as potentially investing $35 million in a private placement that would occur with the closing of a merger with the SPAC. There are no formal agreements in place for these possible investments. Cormorant is a life sciences-focused investment firm with over $2 billion AUM.
The SPAC’s shares trade on the Nasdaq under the symbol HLXB.
Leerink Partners was sole bookrunning manager for the offering. Read more.
